HomePress-release

Redding, California - January 22, 2025

Cardiac Biomarkers Market to be Worth $10.08 Billion by 2031

Cardiac Biomarkers Market Size, Share, Forecast, & Trends Analysis by Type (Troponin, CK-MB, Myoglobin, BNP), Application (Myocardial Infarction, Congestive Heart Failure), and End User (Laboratory Testing, POC Testing ) - Global Forecast to 2031

Meticulous Research^®—a leading market research company, published a research report titled, ‘Cardiac Biomarker Market Size, Share, Forecast, & Trends Analysis by Type (Troponin, CK-MB, Myoglobin, BNP), Application (Myocardial Infarction, Congestive Heart Failure), and End User (Laboratory Testing, POC Testing)- Global Forecast to 2031”. According to this latest publication from Meticulous Research^®, the cardiac biomarkers market is projected to reach $10.08 billion by 2031, at a CAGR of 8.8% from 2024 to 2031.

The growth of cardiac biomarkers market is driven by increasing prevalence of cardiovascular diseases, rising geriatric population, technological advancements in cardiac biomarkers, increasing healthcare expenditure, and increasing cardiovascular disease awareness programs. However, market growth is restrained by the limited specificity and sensitivity of biomarkers and high cost of biomarker testing.

Moreover, introduction of novel biomarkers tests and integration of biomarkers in point-of-care testing are expected to generate growth opportunities for market stakeholders. Alternative diagnostic technologies pose challenges to the growth of the market.

Key Players

The key players profiled in the cardiac biomarkers market report are Abbott Laboratories (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (U.S.), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), bioMérieux SA (France), Danaher Corporation (U.S.), Creative Diagnostics (U.S.), Life Diagnostics, Inc. (U.S.), Randox Laboratories Ltd. (U.K), Becton, Dickinson and Company (U.S.), and QuidelOrtho Corporation (U.S.).

The cardiac biomarkers market is segmented by Type (Troponin, Creatine Kinase MB (CK-MB), Myoglobin, B-Type Natriuretic Peptide (BNP), N-terminal pro B-type natriuretic peptide (NT-proBNP), and Other Types), Application (Myocardial Infarction, Congestive heart failure, Acute Coronary Syndrome, and Other Applications), End User (Laboratory Testing and Point-of-care Testing), and geography. The study also includes an analysis of the regional and country-level markets.

Among the types studied in this report, in 2024, the troponin segment dominated the cardiac biomarkers market with a share of 51.7%. The rising prevalence of diseases directly elevates the demand for troponin testing in healthcare settings. Moreover, technological advancements in troponin testing have improved its accuracy, sensitivity and accessibility. High sensitivity troponin (hs-Tn) assays help in detecting low level of troponin highly accurate detection of heart conditions. These factors are attributed to the largest share of the segment.

Among the application studied in this report, in 2024, the myocardial infarction segment dominated the cardiac biomarkers market. The rising prevalence of heart attacks due to changing lifestyles, environmental factors, and growing geriatric population are the factors attributed to the largest share of segment. According to the World Health Organization (WHO), about 32% of global deaths, out of these, 85% were due to heart attack and stroke in 2019. Every year, around 805,000 individuals in the U.S. have a heart attack. Out of these, 605,000 are first heart attacks (source: Centers for Disease Control and Prevention (CDC)). As the burden of heart attack increases, the demand of advanced diagnostic tools such as cardiac biomarkers increase.

Among the end users studied in this report, in 2024, the laboratory testing segment dominated the cardiac biomarkers market with a share of 59.7%. As partnerships between hospitals and diagnostic laboratories are increasing there has been huge transfer of patients from hospitals to diagnostic laboratories for diseases diagnosis. Moreover, laboratory settings are well equipped with advanced assays and controls which ensure the accuracy and reliability of the results. These factors are attributed to the largest share of the segment.

Among geographies, in 2024, North America dominated the cardiac biomarkers market with a share of 39.5%. The increasing prevalence of cardiovascular diseases coupled with rising geriatric population, increasing sedentary lifestyle, rising consumption of alcohol & caffeine, well-established healthcare system, high awareness of cardiovascular diseases, high healthcare expenditure, and presence of major key players in this region are factors contributing to the largest share of the region in the market.

Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=6131

Key questions answered in the report-

Which are the high-growth market segments in terms of cardiac biomarkers by type, application, end user, and geography?
What was the historical market for cardiac biomarkers across the globe?
What are the market forecasts and estimates for the period 2024–2031?
What are the major drivers, restraints, opportunities, and challenges in the cardiac biomarkers market?
Who are the major players operating in the cardiac biomarkers market?
What is the competitive landscape like, and who are the leaders in the cardiac biomarkers market?
What are the recent developments in the cardiac biomarkers market?
What are the different strategies adopted by the major players in the cardiac biomarkers market?
What are the geographical trends and high-growth regions/countries?

Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research

3D Printing

5G Technology

Advanced Chemical & Materials

Agrochemicals

Algae Products

Alternative Proteins

Animal Health

Artificial Intelligence

Automotive Technologies

Big Data Analytics

Climate Technologies

Edible Insects

Electric Vehicle

Food & Agriculture Technologies

Hydrogen Technologies

Internet Of Things

In Vitro Diagnostics

Laboratory Instrumentation

Language Learning Technologies

Medical Technologies

Next Generation Technologies

Processing & Packaging Technologies

Robotics & Automation

Smart Technologies

Water & Wastewater Technologies

Miscellaneous / Others

Redding, California - January 22, 2025

Cardiac Biomarkers Market to be Worth $10.08 Billion by 2031

Cardiac Biomarkers Market Size, Share, Forecast, & Trends Analysis by Type (Troponin, CK-MB, Myoglobin, BNP), Application (Myocardial Infarction, Congestive Heart Failure), and End User (Laboratory Testing, POC Testing ) - Global Forecast to 2031

Recommended Readings

Advanced Chemical &
Materials

Food & Agriculture
Technologies

Next Generation
Technologies

Processing & Packaging
Technologies

Water & Wastewater
Technologies